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AbstrACt 
Introduction Maternal immunization (MI) with tetanus 
toxoid containing vaccine, is a safe and cost-effective 
way of preventing neonatal tetanus. Given the prospect 
of introducing new maternal vaccines in the near future, 
it is essential to identify and understand current policies, 
practices and unmet needs for introducing and/or scaling up 
MI in low-income and middle-income countries (LMICs).
Methods and analysis The Maternal Immunization and 
Antenatal Care Situation Analysis (MIACSA) is a mixed 
methods, cross-sectional study that will collect data in 
four phases: (1) a review of global databases for selected 
health indicators in 136 LMICs; (2) a structured online 
survey directed at Maternal, Newborn and Child Health 
and Expanded Programme on Immunization focal points 
in all 136 LMICs; (3) semistructured telephone interviews 
of 30 selected LMICs and (4) 10 week-long country visits, 
including key informant interviews, health facility visits 
and focus group discussions. The principal analyses will 
assess correlations between the various aspects of MI 
delivery strategies and proxy measures of health systems 
performance related to vaccine-preventable disease 
control. The primary outcome will be a typology of existing 
MI delivery models, and secondary outcomes will include 
country profiles of child and maternal health indicators, and a 
MI gaps and needs analysis.
Ethics and dissemination The protocol was approved 
by the WHO Ethics Review Committee (ERC.0002908). 
The results will be made available in a project report and 
submitted for publication in peer-reviewed journals that 
will be shared broadly among global health decision-
makers, researchers, product developers and country-level 
stakeholders.
IntroduCtIon
Vaccine-preventable diseases are a major 
cause of global child morbidity and mortality, 
particularly in low-income and middle-income 
countries (LMICs).1 Since the 1990s, public 
health interventions have more than halved 
under-five childhood mortality; however, 
reduction of stillbirths and of neonatal 
mortality (death in the first 28 days of life) 
has been slower.2 This is in part due to the fact 
that most vaccines cannot be administered 
to newborns, who, being unable to develop 
protective responses due to limitations in their 
immune system, are left particularly vulnerable 
to infectious diseases. Vaccination of pregnant 
women, or maternal immunization (MI) with 
tetanus toxoid containing vaccine, has proven 
strengths and limitations of this study
 ► The Maternal Immunization and Antenatal Care 
Situation Analysis (MIACSA)  study provides a first 
time, comprehensive global overview and analy-
sis of existing maternal immunization (MI) delivery 
strategies in low-income and middle-income coun-
tries (LMICs).
 ► The study benefits from a mixed-methods design; 
a multidisciplinary approach leveraging policy-level, 
academic and implementers’ experience.
 ► Limitations include the small number of countries 
and healthcare facilities visited within each country 
included in the study, precluding generalisation of 
country visit findings to a national level.
 ► End-users’ perspective is captured only indirectly 
through community health workers. Data on MI ser-
vice delivery collected through an online survey tar-
geting all LMICs are analysed within the limitations 
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to be an effective strategy to reduce neonatal tetanus, 
and is a potential strategy to reduce the burden of other 
vaccine-preventable diseases in mothers and infants. Thus, 
MI is one of the several strategies that aim to reach the 
third sustainable development goal of ending preventable 
maternal and newborn deaths.3–5 
Studies have shown that MI can effectively protect 
the mother, as well as her child, through transplacental 
transfer of maternal IgG to the fetus.6 7 The Maternal and 
Neonatal Tetanus Elimination (MNTE) initiative has led 
the way in the implementation of MI, combining at least 
two doses of tetanus toxoid-containing vaccine (TTCV) 
during pregnancy (TT2+) with the promotion of hygienic 
delivery and clean cord care practices, as well as vaccina-
tion of children and women of reproductive age, to elim-
inate maternal and neonatal tetanus (MNT) as a public 
health problem. Between the late 1980s and 2015, the 
MNTE initiative reduced global tetanus-related neonatal 
mortality by 96%.8
TTCV and inactivated influenza vaccines are consid-
ered safe and effective for use during pregnancy,9 and are 
recommended for pregnant women by WHO.6 10–13 New 
vaccines, several of which are under development and 
evaluation, target other important pathogens, such as 
group B streptococcus and respiratory syncytial virus, and 
may provide safe and cost-effective protection of mothers 
and their infants through MI in the future.14–18
In order to identify the challenges of implementing 
current and new vaccines for MI, a better understanding 
is needed of the capabilities and limitations of existing 
delivery platforms, such as antenatal care (ANC) services 
and the Expanded Programme on Immunization (EPI).19 
The capacity of ANC services to deliver vaccines to preg-
nant women will require thorough assessment, as glob-
ally, only 62% of women benefit from at least four ANC 
visits, that is, the proportion of pregnant women who 
received four or more ANC visits during their last preg-
nancy (ANC4+), and in Sub-Saharan Africa and South 
Asia, ANC4+ coverage is only 52% and 46%, respectively.20 
Delivering vaccinations and other essential interventions 
to women at the necessary timely intervals during preg-
nancy, as well as documenting the coverage and outcomes 
of such interventions, requires a robust ANC platform 
with sufficient personnel and resources.21
WHO recommends that pregnant women living in 
high-risk areas are sufficiently immunised against tetanus 
in order to protect the women and their newborn infants. 
MI with TTCV is routine in many countries22 23; however, 
the progress of tetanus vaccination in LMICs has faced 
challenges leading to delays in elimination, and uptake 
among pregnant women of other vaccines, such as influ-
enza and pertussis vaccines, has been low. As a part of 
EPI services, routine tetanus immunization during 
pregnancy has been complemented with supplemen-
tary immunization activities in a majority of countries in 
order to reach high coverage and achieve MNTE goals. 
A better understanding of MI in the context of both 
ANC and EPI, including implementation of guidelines 
and policies, ministerial responsibilities at national and 
subnational levels, vaccine management including cold 
chain and logistics, vaccine administration, staff capacity, 
social mobilisation, vaccine acceptance and assessment of 
vaccine safety, may help to identify service delivery chal-
lenges as well as opportunities to optimise current and 
future MI efforts.24
Closer collaboration between ANC and EPI services 
could provide a unique and cost-effective opportunity 
to further strengthen preventive healthcare measures 
for women and children under each programme, by 
reducing missed opportunities for vaccination, including 
MI, as well as reinforcing the delivery of essential health-
care services.
In view of recent product and policy developments, 
WHO, supported by the Bill & Melinda Gates Founda-
tion, aims to identify the knowledge gaps in MI delivery 
strategies by mapping the strengths and challenges of 
existing ANC and EPI services for pregnant women in 
LMICs through the Maternal Immunization and Ante-
natal Care Situation Analysis (MIACSA) project. The 
results will provide the evidence for a typology of MI 
delivery models, as well as identify the capacity needs and 
key system changes required to introduce new maternal 
vaccines and/or strengthen vaccine delivery for MI 
in LMICs. Ultimately, the project aims to identify and 
understand current MI-related and ANC-related policies, 
practices and the need for strengthening maternal child 
healthcare services, and how they could accommodate 
new MI vaccines.
MEthods And AnAlysIs
Patient and public involvement
The development of the research questions was influ-
enced by an interdisciplinary group of international 
experts for the MIACSA project. The project did not 
include patients, but restricted itself to national level 
programme managers and health facilities where health 
workers responded to interviews in their professional 
capacity.
study design and data collection
Between November 2016 and December 2018, a mixed-
methods, cross-sectional study will be carried out in 
four phases to assess key health system features related 
to the implementation of MI (figure 1). An expert advi-
sory panel (EAP), consisting of specialists in immunisa-
tion, maternal and neonatal health, MI implementation 
and social sciences, will provide technical advice on the 
study design, the development of research questions 
and surveys, the data collection methods and the results 
interpretation. In addition to following WHO standards 
for global monitoring surveys, all data collection tools 
and standard operating procedures will be reviewed and 
endorsed by the EAP. The surveys and country visits will 
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Desk review of global data (data collection phase 1)
The first phase will consist of collecting key health indi-
cators of LMICs to create outlines of country profiles, 
focusing on ANC and EPI services. A desk review of 
predefined health indicators (figure 2) from 136 LMICs 
will be conducted from existing global data sources, 
including Demographic and Health Surveys (DHSs)/
Multiple Indicator Cluster Surveys (MICSs), WHO/
United Nations Children’s Fund (Unicef) estimates of 
national immunization coverage, WHO/Unicef Joint 
Reporting Forms (JRFs), MNTE reports and WHO 
Maternal, Newborn, Child and Adolescent Health 
(MNCAH) policy survey. The indicators will focus on 
governance and policy environment, health systems 
performance and immunisation activities, including MI. 
Data from phase 1 will be compiled in a database for anal-
ysis of the study’s research questions, and will inform the 
selection of countries for phase 3 (see  figure 2).
Global online survey (data collection phase 2)
The country profiles established in phase 1 will be 
completed and, if needed, updated by an online survey 
with WHO Regional Offices, national Ministry of Health 
(MoH) focal points from Maternal, Newborn and Child 
Health (MNCH) and EPI programmes and their WHO 
Country Office counterparts in all LMICs, using a struc-
tured questionnaire (figure 3). Data will be collected 
on service delivery models of maternal tetanus vaccina-
tion, including delivery platforms, programme funding, 
disease surveillance and vaccine safety surveillance. Data 
on maternal vaccines other than tetanus will be included 
when pertinent. A draft questionnaire will be piloted in 
advance of the survey. Non-responders will be followed-up 
by telephone and email. Revisions following queries on 
missing, erroneous or inconsistent data will be done at 
country level.
Figure 1 Key health system features studied by the MIACSA project. AEFI, adverse events following immunisation; ANC, 
antenatal care; EPI, Expanded Programme on Immunization; MIACSA, Maternal Immunization and Antenatal Care Situation 
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Telephone interviews (data collection phase 3)
In order to understand how existing healthcare delivery 
services could be adapted to implement MI beyond 
tetanus immunization, further data will be collected on 
delivery platforms for maternal tetanus vaccination in 
LMICs. In-depth telephone interviews will be conducted 
with EPI and MNCH programme officers responsible 
for MI at the MoH in a sample of 30 countries, using 
Figure 2 Study phase 1: list of indicators for the review of global databases. CES, coverage evaluation survey; DPT1, first dose 
of diphtheria–pertussis–tetanus vaccine; DPT3, third dose of diphtheria–pertussis–tetanus vaccine; HepB1, first dose of hepatitis 
B vaccine; HepB3, third dose of hepatitis B vaccine; Hib1, first dose of Haemophilus influenzae type B vaccine; Hib3, third dose 
of H. influenzae type B vaccine; MCV1, first dose of measles-containing vaccine; MCV2, second dose of measles-containing 
vaccine; PCV1, first dose of pneumococcal conjugate vaccine; PcV3, third dose of pneumococcal conjugate vaccine; 
Pol1, first dose of polio-containing vaccine; Pol3, third dose of polio-containing vaccine; RCV1, first dose of rubella-containing 
vaccine; RotaC, second or third dose of rotavirus vaccine depending on number of doses recommended in national schedule; 
TT1, first dose of tetanus toxoid vaccine; TT1+, at least one dose of tetanus toxoid vaccine; TT2, second dose of tetanus 
toxoid vaccine; TT2+, at least two doses of tetanus toxoid vaccine; TT3, third dose of tetanus toxoid vaccine; TT4, fourth dose 
of tetanus toxoid vaccine; TT5, fifth dose of tetanus toxoid vaccine; WUENIC, WHO/United Nations Children’s Fund (Unicef) 
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a semistructured questionnaire (figure 4). The coun-
tries will be selected based on the performance of MI 
as assessed by coverage of maternal TTCV and ANC, 
geographic representation and recommendations from 
WHO Regional Offices on MI priorities. The countries 
will be stratified into four groups; high and low maternal 
tetanus vaccination performance measured as protec-
tion at birth (PAB), that is, the proportion of newborns 
Figure 3 Study phase 2: variables collected from online survey of 136 low-income and middle-income countries (LMICs). A 
structured questionnaire will be used to determine which service delivery platforms are in place for tetanus vaccination 
of pregnant women in LMICs, and to understand how existing health services could be adapted to implement maternal 
immunisation beyond tetanus vaccination. Internal validation questions are incorporated in the questionnaire, and sources 
of data are requested, that is, if administrative data or personal estimates. AEFI, adverse events following immuni; ANC, 
antenatal care; EPI, Expanded Programme on Immunization; HBV, hepatitis B vaccine; OPV, oral polio vaccine; PAB, protection 
at birth; Td, tetanus diphtheria; Tdap, tetanus diphtheria–acellular–pertussis; TT, tetanus toxoid; TT2+, at least two doses of 
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Figure 4 Study phase 3: variables collected from interviews of 30 selected LMICs. A semistructured questionnaire will be 
used to assess the preparedness of antenatal care services for introducing (additional) immunisations for pregnant women 
in selected low-income and lower-middle-income countries, and to understand the strengths and weaknesses of current 
immunisation to guide future planning. Internal validation questions are incorporated and probing for further details will be 
done when deemed necessary by the interviewer(s). Sources of data provided are requested, that is, if administrative data or 
personal estimates. AEFI, adverse events following immuni; ANC, antenatal care; EPI, Expanded Programme on Immunization; 
HMIS, health management information system; LMICs, low-income and middle-income countries; NITAG, national immunisation 
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protected at birth against neonatal tetanus, with a cut-off 
of 90%, and high and low ANC performance (with a 
cut-off of the median ANC4+ coverage in countries with 
available data). PAB was identified as a more reliable 
proxy measure than TT2+, as the issue of not including 
already vaccinated women in the numerator used for esti-
mating the latter indicator would be avoided. The PAB 
cut-off level was set based on the target required to attain 
and sustain MNTE, whereby >80% of pregnant women 
are immunised against tetanus. The country selection 
will include a representation of all MI delivery models 
and WHO regions, with a focus on Africa and South-East 
Asia where maternal and neonatal mortality are highest, 
and will ensure inclusion of high-performing countries 
in order to include likely early adopters of new maternal 
vaccines and learning cases of best practices.
The interviews will collect data on the policy, gover-
nance and funding environment for EPI and ANC 
programmes, ANC delivery and maternal tetanus vaccina-
tion including monitoring and evaluation of results. The 
questionnaire will be shared with WHO Country Office 
focal points and MoH MNCH and EPI managers for 
compilation in advance of the teleconference, allowing 
for discussion and clarification when needed during the 
Figure 5 Study phase 4: country study analysis framework for 10 country visits. Key informant interviews, health facility visits 
and focus group discussions will enable observation and collection of further data on the variables from the previous study 
phases, in particular at different levels of the healthcare system, and of sociocultural and socioeconomic factors. End-users, 
that is, pregnant women, will not be interviewed as it would require a separate study design, and their perspective will be 
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actual interview. Responses will be recorded using stan-
dard data entry procedures, and may be voice-recorded 
if consent is obtained by the interviewees. Any discordant 
responses will be attempted to be resolved by consensus, 
and incomplete responses will be followed-up. A summary 
of key findings will be shared with the participants to 
confirm the responses were correctly captured.
Country visits (data collection phase 4)
Finally, in-country visits will be conducted in order to 
collect data on MI from key decision-makers and imple-
menters at every level of the healthcare system, as well as 
to determine actual delivery, capacity and coordination of 
ANC and EPI services, on both supply and demand sides 
of the healthcare services (figure 5). Ten countries will be 
selected based on the high, medium or low performance 
of MI systems as assessed by PAB and TT2+, a range of 
different MI delivery models (eg, degree of coordination 
between EPI and ANC in MI delivery), and agreement by 
senior national and subnational MNCH and EPI staff for 
study visits. The final country selection will ensure repre-
sentation of the range of MI delivery models, and will 
include high-performing countries, MNTE priority coun-
tries and countries with high ANC4+ coverage. Site visits 
will include ANC and EPI sites and session observations, 
focus group discussions and in-depth interviews. The 
week-long visits will be piloted in two countries to adjust 
and refine the data collection tools and the standard 
operating procedures, and data from these two countries 
will be included in the final analysis.
An initial joint focus group discussion will be held with 
national-level stakeholders, followed by key informant 
interviews with stakeholders pertinent to MI, ANC and 
EPI services at subnational levels of the healthcare system, 
including decision-makers and policy-makers, technical 
and financial parties, and civil society, such as non-gov-
ernmental organisations. The study will aim to conduct 
a total of 12 health facility visits taking into account a 
balance of geographical locations, urban and rural areas, 
and—if possible—different types of health facilities (eg, 
small and large health units). The country visits will be 
concluded with an on-site debriefing and joint data anal-
ysis with MoH MNCH and EPI focal points and other 
main country-level stakeholders. End-users, that is, preg-
nant women, will not be interviewed as it would require 
a separate study design; however, their perspective will be 
indirectly included through the participation of commu-
nity health workers at stakeholder meetings.
data analysis plan
The cross-sectional data analyses will be carried out over 
four data collection phases (desk review of global data, 
online questionnaire, in-depth country interviews and 
country visits). The first three will yield quantitative data. 
The last two data collection phases will also provide an 
in-depth qualitative analysis of data collected from a select 
number of countries. Below, we describe the analyses for 
each phase.
Desk review of global data (phase 1)
The MIACSA project will conduct a desk review of global 
databases (JRF, United Nations mortality reports, DHS, 
MICS, WHO MNCAH policy survey database, MNTE 
database, WHO/Unicef estimates of national immuniza-
tion coverage) targeting 136 LMICs.
The primary outcome variable (dependent vari-
able) to asses MI performance will be PAB (cut-off level 
<90% and ≥90%) and the independent variables will 
include country economic level, immunisation coverage, 
mortality, service coverage, available ANC and vaccina-
tion policies and availability of a National immunisation 
Advisory Committee (figure 2).
We will first asses the database for completeness of data. 
We will also conduct a sensitivity analysis based on impu-
tation of data based on available predictors for countries 
with missing data on PAB. Results from the complete case 
analysis will be compared with the sensitivity analysis to 
explore bias due to missing data.
We will conduct bivariate analyses to assess whether the 
dependent variables are associated with the independent 
variables. We will also do multivariable analyses within 
subgroups, since vaccinations may differ by other factors 
(eg, WHO Regions; Global Alliance for Vaccines and 
Immunization (GAVI) status; World Bank income level; 
MNTE and female literacy rate).
For continuous variables, we will first assess the 
normality using the Shapiro-Wilk test. If needed, we 
will make appropriate transformations to normalise 
the data or group them into categories as necessary. 
We will then compare the distributions of the variables 
by groups with two-sided χ2 (categorical variables) 
or t-tests (continuous variables) or the equivalent 
non-parametric tests (eg, Fisher’s exact or Wilcoxon/
Kruskal-Wallis), as appropriate. A two-sided p value of 
0.05 will be considered significant.
To create a multivariable model, we will include all 
variables that are significantly associated with the depen-
dent variable and those variables that have shown asso-
ciation within the available literature. We will then asses 
for collinearity and remove one of the variables if collin-
earity is found. We will also assess for interactions and will 
create interaction terms to be included in the model if 
any interactions are found. Both forward and backward 
elimination will be conducted to assess the goodness of fit 
and create the final model.
Global online survey (phase 2)
The variables are based on the online survey as 
described in the Desk review of global data (phase 1) 
section. For a summary of the included components see 
figure 3. Data from the online survey will be checked for 
completeness and consistency and coded to reflect skip 
patterns. The complete data set for analyses will include 
PAB from phase 1 (desk review database) and will be 
linked with the database containing responses for the 
global online questionnaire. Descriptive analyses will 
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analyses will be conducted to assess the associations 
between the questionnaire variables and the dependent 
variable PAB and the significance of the relationship 
will be tested with Fisher’s exact test. Logistic regression 
models will be used to assess the relationship between 
the responses in the online questionnaire and high 
coverage of PAB≥90% independently. These models will 
be created as described in phase 1. A two-sided p value 
of 0.05 will be considered significant.
Telephone conferences (quantitative analyses, phase 3)
The primary objective is to provide descriptive informa-
tion about MI services and its organisation (figure 4).
Data from this phase will be checked for complete-
ness and consistency and coded to reflect skip patterns. 
Descriptive analyses will be conducted including 
summary measures.
Qualitative analyses based on country visits and telephone 
conferences (phase 4)
Ten countries will be visited to conduct qualitative 
interviews at national and subnational level. Resulting 
qualitative information from these visits as well as from 
telephone interview conducted in the previous phase 
will be used in a thematic analysis applied by trained 
qualitative data analysts to the following qualitative 
data sources: comments and free-text responses to tele-
phone interview questions (phase 3), semistructured 
interviews with community health workers (phase 4), 
comments and free-text response to stakeholder and 
facility manager interviews (phase 4) and comments 
provided during debrief sessions with national level 
stakeholders in-country (phase 4). Thematic analysis 
will be applied to intracase and cross-case analysis. First, 
an intracase analysis will organise and reduce qualita-
tive findings within each country along two criteria: (1) 
relevance of finding to research questions and (2) rela-
tive frequency of finding across data sources. Second, 
a cross-case analysis will organise findings across coun-
tries into themes generated from research questions 
and subthemes generated from grounded analysis of 
data collected. Two qualitative data analysts will co-or-
ganise and reduce intracountry findings. For cross-
country findings, qualitative analysts will independently 
generate themes and subthemes for cross-case anal-
ysis and will then resolve any intercoder divergence in 
themes and subthemes based on the relevance of theme 
to data source, relevance of theme to research questions 
and robustness of theme relative to alternative themes. 
See figures 4 and 5 for the included components.
Consolidated data analysis
To inform the development of a typology of MI delivery 
models approaches in LMICs quantitative and qualita-
tive data analysis results will be consolidated in a global 
analysis of MI and ANC service delivery approaches in 
countries as well as individual country profiles that shall 
support countries to conduct self-assessments of their 
MI and ANC systems strengths and capacity gaps. On 
the basis of the advice of the project’s advisory group, 
a checklist approach will be considered to provide 
a profiling for countries with sufficient data avail-
able, including indicators on policy and governance, 
financing, programme management, service delivery 
systems and demand-side issues. Ultimately, such a 
profiling shall help countries and other MI stakeholders 
to identify the needs for targeted support to strengthen 
existing MI programmes or to reach readiness to intro-
duce future programmes.
limitations
The data analyses will take into account the limitations 
of the study, including the reliability of the selected 
outcome measures, that is, PAB, potential biases intro-
duced by the limited number of countries for which 
in-depth information will be available, that is, through 
telephone interviews and in-country visits, selective 
sampling of in-country site visit locations, missing 
data and the fact that the end-users’ perspective will 




The first three phases of the study are exempt from 
ethical permission as participants will provide informa-
tion on operations and administration of public health 
services on a purely professional basis, and without 
disclosure of person-identifiable information.
Country ownership will be ensured by transferring 
the responsibility for providing data to in-country focal 
points, and by joint, on-site analysis of the data collected 
during the country visits with the main stakeholders. 
The study aims to contribute to the evidence needed 
to ensure more equitable access to high-impact global 
health interventions, such as MI.25
data management and dissemination
The data will be managed and analysed by data clerks 
who were not part of the data collection. Anony-
mised data from surveys and key informant interviews, 
excluding any confidential information as identified by 
the in-country focal points, will be uploaded to a publicly 
available data repository hosted by the WHO. Record-
ings from country interviews will be transcribed before 
the qualitative analyses and destroyed at the comple-
tion of the data analyses.
The results will be submitted for publication in peer-re-
viewed journals, as well as in a MIACSA project report that 
will be shared widely with global health decision-makers, 
researchers, product developers and implementers. 
The report and/or specific aspects of the project will be 
presented at international stakeholder meetings, with the 
ultimate aim to establish a knowledge network of coun-
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results will be shared through summaries on the WHO 
website and in public fora.
To ensure wide distribution of the project findings 
to the international scientific community and national 
stakeholders involved in MI, findings will be also shared 
at the end of the project through a large stakeholder 
convening. At this meeting, key aspects of maternal 
tetanus vaccination service delivery mechanisms and 
ANC capacities identified in select countries will be 
discussed to enable exchange of lessons learnt between 
select participating countries and to discuss generalis-
able lessons learnt that may improve MI service delivery 
through an integrated platform considering immunisa-
tion and maternal child healthcare mechanisms.
Dissemination of the MIACSA results will aim to 
provide advice on best practices, policy requirements, 
capacity needs and health system changes needed for 
successful introduction and integration of new maternal 
vaccines into national health systems, including ANC 
and EPI services, in LMICs.
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